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Abstract  
 
 
The Sheffield Type 1 Diabetes Policy Model is a patient-level simulation model of type 1 
diabetes and its associated complications, which was developed as part of the National 
Institute for Health Research Dose Adjustment for Normal Eating (DAFNE) research 
programme.   The aim of this paper is to describe the conceptual modelling, model 
implementation, and model validation phases of the Sheffield Type 1 Diabetes Model 
development process.  The model is highly flexible and has broad potential application to 
evaluate DAFNE, other diabetes structured education programmes, and other interventions 
for type 1 diabetes. 
 Introduction 
 
Type 1 diabetes is a metabolic disorder characterised by an almost total deficiency in insulin 
that leads to higher than normal levels of glucose in patients’ blood (termed poor glycaemic 
control).  Once patients are diagnosed with type 1 diabetes they must remain on insulin 
replacement therapy for their lifetime.   Type 1 diabetes is associated with long-term 
microvascular complications (neuropathy, nephropathy, retinopathy, and macular oedema) 
and macrovascular complications (myocardial infarction (MI), heart failure (HF), stroke, and 
angina) which can lead to serious consequences such as limb amputation, blindness, 
disability and death. These diabetes-related complications account for most of the increased 
morbidity and mortality associated with type 1 diabetes1.  The risk of long-term complications 
is  related  to  patients’  glycaemic  control,  which  is  most  commonly  assessed  using 
glycosylated haemoglobin (HbA1c), an average measure of blood glucose levels over time. 
Patients with type 1 diabetes are also at risk of acute complications: hypoglycaemia 
(excessively low blood glucose caused by taking too much insulin) and diabetic ketoacidosis 
(DKA) (high levels of ketones in the blood caused by high blood glucose levels).  Both long- 
term and acute diabetic complications are associated with substantial healthcare costs and 
affect patients’ quality of life (QoL) and their mortality risk. 
 
 
In the UK it is recommended that all patients with type 1 diabetes are offered a structured 
education programme (SEP) to support their diabetes self-management2.  The only SEP in 
the UK currently meeting the nationally agreed criteria is the Dose Adjustment For Normal 
Eating (DAFNE) course3.   DAFNE is a five-day outpatient SEP aimed at providing adults 
with type 1 diabetes with the skills and confidence to estimate the carbohydrate content of 
meals and adjust their insulin doses to match food portions4.  A randomised controlled trial 
(RCT) of 169 patients with type 1 diabetes demonstrated that DAFNE significantly improved 
HbA1c, dietary freedom and overall QoL compared with no DAFNE, without increasing the 
rate of hypoglycaemia5.  A published cost-effectiveness analysis of DAFNE compared with 
no DAFNE suggested that the intervention was cost-effective and would pay for itself within 
five years6.  The National Institute for Health Research (NIHR) funded a five-year research 
programme to investigate in more detail the factors affecting the success of DAFNE7.  The 
programme, entitled “Improving Management of Type 1 Diabetes in the UK: The DAFNE 
Programme as a Research Test-bed”, was underpinned by health economic analyses. 
 
 
The health economic analyses underpinning this research programme included the 
development of a new health economic model to evaluate the cost-effectiveness of evolving 
forms of the DAFNE intervention.   This research was undertaken at the University of 
Sheffield.     The  aim  of  this  paper  is  to  describe  the  conceptual  modelling,  model 
 implementation, and model validation phases of the Sheffield Type 1 Diabetes Model 
development process. The paper first outlines how the model was conceptually designed, 
then describes how it was implemented in the simulation software Simul8® and the key 
features of the model and its inputs. The results of the internal validation are provided. 
Finally the paper presents a discussion of the strengths and weaknesses of the Sheffield 
Type 1 Diabetes Model. 
 
 
Conceptual Modelling 
 
The conceptual modelling phase of the model development process included two workshops 
with clinical and social science experts in diabetes, a systematic review of published models 
of type 1 diabetes, and structured decision making by researchers at the University of 
Sheffield. An initial workshop (Workshop 1) was held in June 2009 with invited clinical 
diabetes specialists (including a nurse specialist) and the University of Sheffield DAFNE 
health economics team to understand the natural history of type 1 diabetes. The next stage 
of the conceptual modelling process was a systematic review of previously published cost- 
effectiveness models of type 1 diabetes. A total of 65 papers, relating to 32 individual cost- 
effectiveness models, were selected for inclusion in the review (details available from the 
authors on request).   A draft model structure including all potential diabetes-related 
complications was then developed based on the systematic review of previous cost- 
effectiveness models. In July 2010, the University of Sheffield DAFNE health economics 
team conducted a second workshop (Workshop 2) with clinical experts to discuss the results 
of  the  review  and  the  proposed  conceptual  model.  The  final  conceptual  model  was 
developed after discussions in the workshop and is as shown in Figure 1. 
 
 
Model Description 
 
The Sheffield Type 1 Diabetes Model is a flexible and comprehensive long-term simulated 
patient-level Markov model incorporating the most up-to-date methodologies (such as 
capturing parameter uncertainty, time profile of patient characteristics and including patient 
behaviour) to allow a number of cost-effectiveness evaluations. 
 
 
The Sheffield Type 1 Diabetes model consists of a series of sub-models simulating the 
progression of each of the diabetic complications, acute complications and mortality in a 
given population with type 1 diabetes. The model allows each simulated patient to develop 
multiple complications and for the incidence of these complications to be dependent upon 
simulated patients’ individual characteristics. The individual patient characteristics include 
demographics (age, gender and duration of diabetes), clinical variables (HbA1c, high density 
lipoprotein (HDL), smoking status, blood pressure and cholesterol), existing diabetes-related 
 complications and treatment status. The complications included in the model are 
nephropathy, retinopathy, neuropathy, severe hypoglycaemia, MI, stroke, HF and angina 
while the adverse events included hypoglycaemia and DKA, as shown in Figure 1. The 
progression of long-term diabetic complications are modelled using transition probabilities 
with an annual time cycle and the adverse events are modelled as annual incidence, for 
each individual patient based on their characteristics (patient behaviour can also be 
incorporated in the model by updating HbA1c and other variables over  time). Each health 
state is associated with an annual cost and a utility value which is combined with the number 
of annual time cycles the patient spends in that health state to estimate costs and quality- 
adjusted life years (QALYs). Some disease progression events are associated with a one-off 
transition cost that is incurred in the transition year. Costs and QALYs are summed across 
time and patients to provide total and average cost and QALY estimates for use in cost- 
effectiveness analyses. 
 
 
Figure 1. Structure of the Sheffield Type 1 Diabetes Model 
 
 
 
 
 
 
Microvascular Complications 
 
The risk of development and progression of nephropathy, neuropathy and retinopathy are 
modelled according to event rates reported in published randomised controlled trials (RCTs) 
and  observational  studies.     Cohort  Markov  models  were  used  to  estimate  annual 
 probabilities of transitioning between states within a particular complication, by combining 
data from multiple sources, assuming a reference HbA1c of 10%. The process was the 
same for all the microvascular complications (retinopathy, nephropathy, neuropathy and 
macular  oedema)  and  full  details  of  these methods  are  available  from  the authors  on 
request.. For each microvascular complication, patients progress to the more severe health 
states within each annual time cycle according to the probabilities reported in Table 1. As the 
probabilities are estimated at the reference HbA1c of 10%, Eastman’s method8 was used to 
adjust the risk of background retinopathy, macular oedema, proliferative retinopathy, 
microalbuminuria, macroalbuminuria, and neuropathy for patients with different HbA1c levels 
(PHbA1c) using the formula: 
 
 
PHbA1c = PHbA1c=10(HbA1c/10)^β (Equation 1) 
 
 
Where is the baseline probabilities PHbA1c=10 are as shown in the Table 1 and the coefficients 
β are as shown in the footnote of Table 1. The rest of the transition probabilities are 
assumed to be independent of HbA1c levels. 
 
 
Table 1. Annual probability of microvascular events 
 
Neuropathy 
 
Parameter Base case 
value 
Source(s) 
Annual transition probabilities for microvascular complications 
Healthy to clinically confirmed neuropathya 0.0354 DCCT,
9 Moss et 
al10 (WESDR) Healthy to PAD with amputation 0.0003 
Clinically confirmed neuropathy to PAD with 
amputation 
0.0154 
a 
β coefficient for neuropathy = 5.30 
 
 
Nephropathy 
 
Parameter Base case 
value 
Source(s) 
Annual transition probabilities for microvascular complications 
Healthy to microalbuminuriaa 0.0436 
 
 
 
 
 
DCCT11, Wong el 
al12 (WESDR), 
UKPDS 3313 
Healthy to macroalbuminuriab 0.0037 
Healthy to ESRD 0.0002 
Healthy to death from ESRD 3.3e-06 
b Microalbuminuria to macroalbuminuria 0.1565 
Microalbuminuria to ESRD 0.0133 
Microalbuminuria to death from ESRD 0.0004 
Macroalbuminuria to ESRD 0.1579 
Macroalbuminuria to death from ESRD 0.0070 
ESRD to death from ESRD 0.0884 
a 
β coefficient for microalbuminuria = 3.25 
b 
β coefficient for macroalbuminuria = 7.95 
  
Retinopathy and macular oedema 
 
Parameter Base case 
value 
Source(s) 
Annual transition probabilities for microvascular complications 
Healthy to background retinopathya 0.0454  
 
 
 
 
WESDR XXII14 
Healthy to proliferative retinopathyb 0.0013 
Healthy to macular oedemac 0.0012 
Healthy to blindness 1.9e-06 
Background retinopathy to proliferative retinopathyb 0.0595 
Background retinopathy to macular oedemac 0.0512 
Background retinopathy to blindness 0.0001 
Proliferative retinopathy to blindness 0.0038 
Macular oedema to blindness 0.0016 
a 
β coefficient for background retinopathy = 10.10 
b  
β coefficient for proliferative retinopathy = 6.30 
c 
β coefficient for macular oedema = 1.20 
 
 
Macrovascular Complications 
The risks of fatal and non-fatal macrovascular complications (MI, stroke, HF and angina) are 
modelled in three stages.  First, the annual probability of experiencing any cardiovascular 
event, P_CVD, is estimated based on patients’ characteristics as per Cederholm et al’s 5- 
year cardiovascular risk model15: 
 
 
P_CVD = 1-exp(-(-(ln(1 - 5year_CVD_risk))/5)*1) (Equation 2) 
Where 5year_CVD_risk is given by the equation 
5year_CVD_risk = (1–0.97136exp [0.08426 × (duration–28.014) + 0.04742 × (age–duration– 
 
16.601) + 0.80050 × (log(TC:HDL)–1.1470) + 1.27275 × (log(HbA1c(DCCT))–2.0605) + 1.20050 × (log(systolic BP)– 
4.8598) + 0.56688 × (smoker–0.1483) + 0.41995 × (macroalbuminuria–0.1237) + 1.25506 × (previous CVD–0.0612)] ) 
(Equation 3) 
 
The P_CVD probability is compared with a random number and if the random number is 
lower than the estimated probability then the patient is deemed to experience a 
cardiovascular event. Secondly, for those patients that experience an event, another random 
number is then used to determine what type of event it was (MI, stroke, HF or angina) using 
methods outlined in Palmer’s 2012 thesis16, based on data from the Diabetes Control and 
Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) 
study17. Given a cardiovascular event, there is a 53% chance that is MI, 28% chance that it 
is angina, 12% chance that it is HF and 7% chance of stroke, as shown in Table 2. Thirdly, if 
the event experienced is an MI, stroke or HF, further random numbers are then used to 
 determine whether the event is fatal using methods outline in Palmer’s 2012 thesis16 and as 
shown in Table 3. 
 
 
Table 2 Probability of different cardiovascular events 
 
Parameter Base case 
value 
Gamma Distribution Source(s) 
alpha beta 
MI 0.53 1 0.0053  
 
 
 
DCCT/EDIC17 
Stroke 0.07 1 0.0007 
Angina 0.28 1 0.0028 
HF 0.12 1 0.00126 
 
 
Table 3. Probability of dying from cardiovascular events 
 
Parameter Base case 
value 
Gamma 
Distribution 
Source(s) 
alpha beta 
MI death  in hospital: Men 0.3930 1 0.00393 Sonke et al18 
MI death  in hospital: Women 0.3640 1 0.00364 Sonke et al18 
MI death within one year: Aged < 
 
65 years 
0.1522 1 0.00152 Malmberg et al19 
MI death within one year: Aged 65- 
 
75 years 
0.1860 1 0.00186 Malmberg et al19 
MI death within one year: Aged > 
 
75 years 
0.2508 1 0.00250 Malmberg et al19 
Stroke death within 30 days 0.1240 1 0.00124 Eriksson et al20 
Stroke death within one year 0.1063 1 0.00106 DCCT/EDIC17 
HF death within one year 0.0570 1 0.00057 Anselmino et al21 
 
 
Acute Complications 
 
Two acute complications are simulated in the Sheffield Type 1 Diabetes Model: severe 
hypoglycaemia (defined as a hypoglycaemic event that the person with type 1 diabetes is 
unable to treat themselves) and DKA.  The model parameters on the incidence of these two 
events were estimated from the DAFNE Research Database and the original DAFNE vs. no 
DAFNE RCT dataset22. Negative binomial models were developed to predict the annual 
rates and the results of the models are presented in Table 4. These models were inputted 
into R software to generate 10,000 samples of the number of severe hypoglycaemic and 
DKA episodes for patients with HbA1c values from 4% to 16% in 0.1% increments.  The 
simulated samples were used to define probability distributions which random numbers were 
compared to within the model in order to determine how many events each simulated patient 
 1 
had in each year (based on their HbA1c value and whether they had received DAFNE or 
not).  Full details of these methods are available from the authors on request. 
 
Table 4: Negative binomial models of the annual number of severe hypoglycaemic 
and DKA episodes 
 
 Coefficient Standard error 95% confidence interval 
Severe hypoglycaemia 
Intercept Β1H 0.928 0.553 (-0.155, 2.012) 
HbA1c Β2H -0.113 0.064 (-0.259, -0.006) 
DKA 
Intercept Β1K -8.108 1.097 (-10.259, -5.958) 
HbA1c Β2K 0.617 0.115 (0.392, 0.842) 
a 
the negative binomial model is Log(number of events) = Intercept B + (Β2*HbA1c) + error 
 
 
Mortality 
 
Patients can also die due to other causes (than due to ESRD and CVD) and this other cause 
mortality is modelled based on UK Interim Life Tables from 2008-1023.  The model compares 
random numbers to gender- and age-specific annual probabilities of death and if the random 
number is lower than the probability of death then the patient is simulated to be dead.  The 
model allows for other life tables to be selected e.g. there is an option to select US mortality 
data used in the CORE model24 or mortality rates from the EAGLE model25. 
 
 
Treatment Effectiveness 
 
HbA1c is the primary method of accounting for treatment effects in the model. However, 
intervention effects on other risk factors such as blood pressure, cholesterol or severe 
hypoglycaemia can also be incorporated and the profiles of the risk factors over time can be 
updated annually. HbA1c change as a result of an intervention has an impact on the risk of 
developing several microvascular complications and this effect is modelled based on 
Eastman’s method8 of adjusting the risk for changes in HbA1c levels as outlined above.  For 
macrovascular complications, the coefficients for HbA1c, HDL, smoking status, blood 
pressure or cholesterol used in Cederholm et al15 were used to adjust the probability of any 
cardiovascular   event.      Finally,   the   effect   of   interventions   on   outcomes   such   as 
hypoglycaemia and DKA can be input directly into the model by the user. 
 
 
Utilities 
 
The model calculates long-term QALYs by using utility values for the health states from the 
literature,  reported  in  Table  5.  Each  health  state  is  associated  with  a  disutility  value 
 (negative) which is added to the baseline utility to estimate the utility in the given health 
state.  In case of multiple complications, the utilities are estimated by aggregating the 
disutilities of the multiple complications to the baseline utility. The lifetime QALYs for each 
patient are estimated based on patients’ life expectancy and their corresponding annual 
utilities.  The model has the flexibility to use alternative utility values as inputted by the model 
user. 
 
 
Table 5:         Base case utility parameters 
 
Health state or event Utility Beta distribution Source(s) 
Alpha Beta 
Baseline utility values 
Male  with  type  1  diabetes  and  no 
 
complications 
0.672 3022.176 1475.11 Coffey26 
Utility decrements 
Complications or covariates Disutility Gamma Distribution Source(s) 
Alpha Beta 
Female with type 1 diabetes and no 
 
complications 
-0.033 17.01563 0.001939 Coffey26 
Blindness -0.208 256 0.000813 Assumption 
Macroalbuminuria -0.017 2.89 0.005882 Coffey26 
ESRD -0.023 0.725652 0.031696 Coffey26 
Clinically confirmed neuropathy -0.055 30.25 0.001818 Coffey26 
PAD with amputation -0.116 25.43667 0.004561 Coffey26 
Background retinopathy - - - Assumption 
Proliferative retinopathy - - - Assumption 
Macular oedema - - - Assumption 
MI (assumed equal to HF) -0.058 6.950413 0.008345 Coffey26 
Stroke -0.018 0.669421 0.026889 Coffey26 
HF -0.058 6.950413 0.008345 Coffey26 
Angina -0.090 24.00912 0.003749 UKPDS 62 
Severe hypoglycaemia -0.071 Samples Samples Walters et 
 
al27 
DKA (assumed equal to severe hypo 
 
but without ongoing utility decrement 
due to fear of hypos) 
-0.001 Samples Samples Walters et 
 
al27 
 Costs 
 
The model calculates long-term costs by using health state costs values from the literature, 
as presented in Table 6.  Each health state is associated with an annual cost which is 
combined with the number of annual time cycles the patient spends in that health state to 
estimate the costs. In case of multiple complications, the costs are estimated by aggregating 
the annual costs of the different complications. Some disease progression events are also 
associated with a one-off transition cost that is incurred in the transition year. All costs have 
been inflated to 2010/11 prices using Personal Social Services Research Unit inflation 
indices28. The model has the flexibility to use alternative cost profiles as inputted by the 
model user. 
 
 
Table 6:         Base case health state and transition costs 
 
 Mean 
Costs 
Gamma Distribution Source 
Alpha Beta 
Microalbuminuria  (ongoing) £34 100 0.34 BNF29, McEwan et al30 
Macroalbuminuria (ongoing) £34 100 0.34 BNF29, McEwan et al30 
ESRD (ongoing) £23,275 100 232.75 NHS Reference Costs31 
Clin Conf Neuropathy £258 100 2.58 Currie et al32 
 
 
 
Clinical Neuropathy 
£258 100 2.58 Assumed equal to 
clinical confirmed 
neuropathy 
Diab foot syndrome £2,713 100 27.13 NHS Reference Costs31 
PAD with amputation (year 1) £6,878 100 68.78 NHS Reference Costs31 
PAD with amputation (ongoing) £418 100 4.18 McEwan et al30 
Background Retinopathy £138 100 1.38 McEwan et al30 
Proliferative Retinopathy £630 100 6.30 McEwan et al30 
Macular edema £630 100 6.30 Assumed equal to 
proliferative retinopathy 
Blindness (year 1) £1,509 100 15.09 UKPDS 65
33
 
Blindness (ongoing) £494 100 4.94 UKPDS 65
33
 
First MI (year 1) £6,465 100 64.65 UKPDS 65
33
 
Second MI £6,465 100 64.65 UKPDS 65
33
 
Final MI £6,465 100 64.65 UKPDS 65
33
 
MI (ongoing) £861 100 8.61 UKPDS 65
33
 
Fatal MI £2,001 100 20.01 UKPDS 65
33
 
First Stroke (year 1) £4,154 100 41.54 UKPDS 65
33
 
Second Stroke £4,154 100 41.54 UKPDS 65
33
 
First Stroke (ongoing) £532 100 5.32 UKPDS 65
33
 
Fatal Stroke £5,414 100 54.14 UKPDS 65
33
 
HF (year 1) £3,637 100 36.37 UKPDS 65
33
 
HF (ongoing) £1,117 100 11.17 UKPDS 65
33
 
  
Fatal HF £3,637 100 36.37 UKPDS 65
33
 
Angina (year 1) £3,236 100 32.36 UKPDS 65
33
 
Angina (ongoing) £906 100 9.06 UKPDS 65
33
 
Hypos £178 100 1.78 Our calculation 
Hypos with Comma £702 100 7.02 Assumed equal to hypo 
w/ hosp 
 
Hypos with Hospitalisation 
 
£702 
 
100 
 
7.02 
NHS Reference Costs31 
 
 
DKA with Hospitalisation 
 
 
£1,333 
 
 
100 
 
 
13.33 
NHS Reference Costs31 
Cost of a diabetic patient with no 
complications 
 
£4,212 
 
100 
 
42.12 
 
UKPDS 6533 
 
 
Other Model details 
 
The model was developed in line with the modelling good practice guidelines34, 
recommendations from the American Diabetes Association35 and published checklists for 
economic evaluation36,37. The model uses an annual discount rate of 3.5% as default (for 
both costs and QALYs, as recommended by NICE38). The model takes a health service 
perspective and uses a lifetime horizon (i.e. until all simulated patients have died) as default 
but the perspective and time horizon are flexible and can be set by the model user. The 
model is capable of performing probabilistic sensitivity analysis (PSA) allowing the effects of 
parameter uncertainty to be captured and the likelihood that interventions are cost-effective 
to be reported. The decision uncertainty is estimated using probability distributions (or a 
collection of random samples) for uncertain parameters. Where parameters were correlated 
and the covariance matrix was known, the random samples were drawn from a multivariate 
distribution. 
 
 
Model Flexibility 
 
The model, programmed in Simul8® software, was developed in a flexible manner that 
allows alternative sets of input data. The user can select whether to perform a deterministic 
analysis or conduct PSA, whereby model parameters are sampled from probability 
distributions. The model also has several option dialogs that allow the user to change the 
time horizon, discount rates for costs and QALYs, patient cohort characteristics, cohort size, 
treatment effects, and cost and utility sources. The Sheffield Type 1 Diabetes Model is highly 
flexible to allow for a large number of differing cost-effectiveness analyses to be undertaken. 
 
 
Model Outputs 
 
The model also allows tracking the history of each of the patients every year which allows 
easy verification and validation of the model. This includes the patient characteristics (i.e. 
HbA1c,  SBP,  HDL,  etc),  incidence  of  acute  complications  (i.e.  hypos  and  DKA),  and 
 microvascular and macrovascular complication status (i.e. disease progression) for each 
year the patient is alive. The aggregated numbers of patients in different health states are 
output each year and the total numbers of each event are also output at the end of the 
lifetime horizon. The costs and utility values, including the split of costs and disutilities by 
complication, are output for each patient for every year they are alive. The total discounted 
costs and QALYs are also output at the end of the lifetime horizon. When performing PSA, 
for the sake of efficiency, the model does not track the history of each patient every year but 
outputs the total costs, QALYs and the numbers of events in each complication for each 
PSA run. 
 
 
Model Verification 
 
Internal verification of the model code (visual logic in Simul8®) was conducted throughout 
the model implementation process. Patient characteristics and complication statuses were 
checked to ensure that they were changing as expected, and that patients were following 
expected routes. The costs and utility value outputs each year were checked against the 
patient status outputs for face validity. The aggregated outputs were also cross checked 
against the sum of individual patient outputs. Second-order validation was also conducted, 
whereby  the  risk  model  was  internally  validated  against  the  data  from  which  it  was 
estimated. 
 
 
Results 
 
The results of second-order validation, which compared the model results with the data from 
the studies used to build the model, are as shown in Table 7. For microvascular 
complications, the normalised differences between model results and the published data 
ranged between 0-15%, except for the deaths from ESRD (which is more than 50%, but can 
be attributed to low event rates) and neuropathy events (~ 25%), with most difference less 
than 10%. For macrovascular complications, the normalised differences between model 
results and the published data ranged between 0-10%, with most differences less than 5%. 
 
 
Table 7. Results of second order validation 
 
 
Microvascular 
Complication 
 
 
Source 
 
Observed 
incidence (%) 
 
Modelled 
incidence (%) 
Nephropathy 
Microalbuminuria DCCT11 20% 17% 
Macroalbuminuria Wong el al12 (WESDR) 33% 27% 
  
ESRD Wong el al12 (WESDR) 20% 18% 
Death from 
ESRD 
UKPDS 3313 0.26% 0.11% 
Retinopathy 
BDR WESDR XXII14 80% 64% 
PDR WESDR XXII14 39% 40% 
ME WESDR XXII14 26% 18% 
Blindness WESDR XXII14 2.3% 2.3% 
Neuropathy 
Neuropathy DCCT,9 9.3% 11.9% 
Amputation Moss et al10 (WESDR) 9.6% 9.5% 
 
Macrovascular 
Complication 
 
Source 
Observed % of 
total events 
Modelled % of 
total events 
 
 
MI 
 
Cederholm et al,15 Palmer’s 
thesis16 
 
 
53% 
 
 
52% 
 
 
Stroke 
Cederholm et al,15 Palmer’s 
thesis16 
 
 
7% 
 
 
7% 
 
HF 
Cederholm et al,15 Palmer’s 
thesis16 
 
12% 
 
13% 
 
Angina 
Cederholm et al,15 Palmer’s 
thesis16 
 
28% 
 
29% 
 
All CVD 
 
Cederholm et al15 
 
5.41% 
 
5.61% 
 
 
Discussion and Conclusions 
 
The Sheffield Type 1 Diabetes Model has several key strengths.  Firstly, the model is based 
on a structured conceptual modelling process that included input from multidisciplinary 
experts in the fields of clinical diabetes, psychology, diabetes education, and simulation 
modelling.    This  structured  process  ensured  that  the  development  of  the  model  was 
evidence-based and that the model is fit for purpose from a number of disciplinary 
perspectives.   Secondly, the model is highly flexible, allowing users to specify the 
characteristics of simulated patients, the time horizon, the cohort size, how treatment effects 
are accounted for, what outcomes are tracked by the model, and whether to run the model 
deterministically or probabilistically.  This high level of flexibility allows the model to be 
adapted to the user’s particular research question, setting, or population of interest and 
broadens the model’s potential applications.  Thirdly, the model is a patient-level simulation 
 which offers the advantage of being able to account for individual differences between 
patients. Fourthly,  the model allows for  patients’ psychological and behavioural 
characteristics and their impact on treatment effectiveness to be incorporated into analyses. 
These two features of the model are particularly useful for investigating heterogeneous 
populations or subgroups.  Finally, the model is structured to facilitate probabilistic sensitivity 
analysis which accounts for uncertainty in the model parameters and is recommended by 
several health technology assessment agencies including NICE38. 
 
 
Despite its many advantages the Sheffield Type 1 Diabetes Model also has some limitations. 
The Sheffield Type 1 Diabetes Policy Model used published data from non-UK settings to 
define risk of long-term complications, some of which are now very old. The risk of long-term 
macrovascular complications is dependent mainly on HbA1c and the effect of other risk 
factors is not captured, which might cause bias when evaluating interventions that affect risk 
factors other than HbA1c. Although the uncertainty in most of the parameters is incorporated 
into the model, uncertainty in some parameters (e.g. coefficients of the risk equations) is not 
captured. 
 
 
Future Research/Planned Analysis 
 
The Sheffield Type 1 Diabetes model was developed as part of the NIHR DAFNE research 
programme and several model-based evaluations are planned as part of that programme. 
Firstly, the model will be used to update the cost-effectiveness results reported by Shearer et 
al6 to include the effects of DAFNE on long-term incidence of macrovascular as well as 
microvascular  complications.    Secondly,  the  model  will  be  used  to  evaluate  DAFNE 
delivered  one  day  per  week  over  five  weeks  compared  with  original  DAFNE  (five 
consecutive days) and thirdly, to evaluate DAFNE plus insulin pumps versus DAFNE plus 
MDI.  The Sheffield Type 1 Diabetes model can also be used to evaluate any (i.e. non- 
DAFNE) interventions for type 1 diabetes. There are also plans to re-estimate the risk 
equations from longitudinal data from DAFNE research database and the long-term follow- 
up data from DCCT/EDIC. Several additions and adaptations to the model are also planned. 
Planned changes include addition of alternative cost and utility input databases from DAFNE 
research database and/or RCTs. 
 
 
Summary 
 
In summary, the Sheffield Type 1 Diabetes Model offers a new whole disease model of type 
 
1  diabetes  and  its  associated  complications.    The  model  development  process  was 
evidence-based and in consultation with multi-disciplinary experts.  The model is highly 
flexible and has broad potential application to evaluate DAFNE, other diabetes structured 
 education programmes, and other interventions for type 1 diabetes.  The model is under 
constant development and updating and several adaptations are planned. 
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